
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT
- About
NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: NAMS (3-star) is a STRONG-BUY. BUY since 45 days. Profits (22.78%). Updated daily EoD!
1 Year Target Price $40.39
1 Year Target Price $40.39
5 | Strong Buy |
4 | Buy |
0 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 98.35% | Avg. Invested days 41 | Today’s Advisory Strong Buy |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.83B USD | Price to earnings Ratio - | 1Y Target Price 40.39 |
Price to earnings Ratio - | 1Y Target Price 40.39 | ||
Volume (30-day avg) 9 | Beta -0.01 | 52 Weeks Range 14.06 - 27.29 | Updated Date 08/15/2025 |
52 Weeks Range 14.06 - 27.29 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.59 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date 2025-08-07 | When Before Market | Estimate -0.44 | Actual -0.15 |
Profitability
Profit Margin -258.91% | Operating Margin (TTM) -186.13% |
Management Effectiveness
Return on Assets (TTM) -17.12% | Return on Equity (TTM) -28.43% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 2096024287 | Price to Sales(TTM) 44.29 |
Enterprise Value 2096024287 | Price to Sales(TTM) 44.29 | ||
Enterprise Value to Revenue 32.75 | Enterprise Value to EBITDA 27.63 | Shares Outstanding 112628000 | Shares Floating 55257774 |
Shares Outstanding 112628000 | Shares Floating 55257774 | ||
Percent Insiders 0.39 | Percent Institutions 111.74 |
Upturn AI SWOT
NewAmsterdam Pharma Company N.V. Ordinary Shares
Company Overview
History and Background
NewAmsterdam Pharma is a late-stage biopharmaceutical company focused on the research and development of transformative therapies for cardio-metabolic diseases with high unmet medical need. It was founded in 2019 and merged with a SPAC in 2022 to go public. Initial focus is on cholesterol reduction.
Core Business Areas
- Lipid Metabolism Therapies: Focuses on developing therapies that modulate lipid metabolism, primarily targeting elevated LDL-C and triglyceride levels to reduce cardiovascular risk.
Leadership and Structure
Michael Davidson, MD, is the Chief Executive Officer. The company has a board of directors with experience in the pharmaceutical industry and finance.
Top Products and Market Share
Key Offerings
- Obicetrapib: Obicetrapib is a cholesteryl ester transfer protein (CETP) inhibitor being developed for lowering LDL-C levels. It's in Phase 3 clinical trials. Competitors include statins (e.g., atorvastatin, rosuvastatin) and PCSK9 inhibitors (e.g., evolocumab, alirocumab). Market share is currently 0% as it is still in development.
Market Dynamics
Industry Overview
The market for lipid-lowering therapies is large and growing, driven by the increasing prevalence of cardiovascular disease and related risk factors. The industry is competitive, with both established pharmaceutical companies and emerging biotech firms.
Positioning
NewAmsterdam Pharma aims to carve out a niche by providing a novel oral CETP inhibitor, potentially offering advantages over existing injectable PCSK9 inhibitors. Success depends on positive clinical trial results and successful commercialization.
Total Addressable Market (TAM)
The global lipid-lowering drug market is estimated at hundreds of billions of dollars. NewAmsterdam is positioned to capture a significant portion through Obicetrapib if approved and demonstrating superior efficacy and tolerability.
Upturn SWOT Analysis
Strengths
- Novel CETP inhibitor with potential for significant LDL-C reduction
- Oral formulation offers patient convenience over injectable PCSK9 inhibitors
- Experienced management team
- Focus on a large and growing market
Weaknesses
- Development stage company with no currently marketed products
- High reliance on the success of Obicetrapib
- Limited financial resources compared to larger pharmaceutical companies
- CETP inhibitors have had historical safety concerns in other drugs of the same class
Opportunities
- Positive clinical trial results could lead to rapid regulatory approval
- Partnerships with larger pharmaceutical companies for commercialization
- Expansion into other cardio-metabolic indications
- Address high unmet needs in patients not well controlled on current therapies
Threats
- Clinical trial failures or safety concerns
- Competition from existing and emerging therapies
- Pricing pressures from payers
- Regulatory hurdles
Competitors and Market Share
Key Competitors
- AMGN
- REGN
- NVO
- LLY
Competitive Landscape
NewAmsterdam Pharma faces competition from established pharmaceutical companies with marketed lipid-lowering therapies and other companies developing novel therapies. Its competitive advantage lies in the potential of Obicetrapib to offer a convenient and effective oral treatment option.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited as it is development stage.
Future Projections: Future growth depends on the successful development and commercialization of Obicetrapib and other pipeline products. Analyst estimates vary widely based on clinical trial outcomes.
Recent Initiatives: Recent initiatives include advancing Phase 3 clinical trials for Obicetrapib, exploring potential partnerships, and evaluating new targets in cardio-metabolic disease.
Summary
NewAmsterdam Pharma is a high-risk, high-reward company focused on developing Obicetrapib, a novel CETP inhibitor, for lowering LDL-C. Its success hinges on positive clinical trial data and successful commercialization. While promising, the company faces competition and regulatory hurdles. The company must continue to grow its resources and reduce spending while commercializing its products.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and should not be construed as investment advice. Financial data and market share estimates are subject to change. Consult a financial professional before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About NewAmsterdam Pharma Company N.V. Ordinary Shares
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2022-11-23 | CEO, President, Executive Board Member & Director Dr. Michael Harvey Davidson FACC, Facp., M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 68 | |
Full time employees 68 |
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.